Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.----[1] 276
2BGJ398 (also known as BBP-831)----[1] 276
3BMN 111----[1] 276
4C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker[1] Polyethylene glycol[1] D03370 --[1] 276
5C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER[1] Polyethylene glycol[1] D03370 --[1] 276
6Growth hormone[1] Somatotropin---[14] 2, 13, 19, 46, 78, 96, 107, 187, 191, 193, 195, 265, 276, 299
7Human Growth Hormone[1] Somatotropin---[5] 78, 187, 193, 265, 276
8INFIGRATINIB[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
9Infigratinib 0.016 mg/kg[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
10Infigratinib 0.032 mg/kg[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
11Infigratinib 0.064 mg/kg[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
12Infigratinib 0.128 mg/kg[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
13Infigratinib 0.25 mg/kg[1] Infigratinib[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
14Infigratinib phosphate[2] Infigratinib,
Phosphate ion		[1] D11589 [3] FGFR1,
FGFR2,
FGFR3 💬		[21] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬[1] 276
15Modified recombinant human c-type----[1] 276
16Modified recombinant human C-type natriuretic peptide----[1] 276
17MODIFIED RHCNP----[1] 276
18Natriuretic peptide----[1] 276
19Normal Saline----[18] 6, 13, 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 271, 276, 296, 299
20PF-07256472----[1] 276
21Phosphate[1] Phosphate ion---[32] 2, 3, 6, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299
22Placebo----[28] 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276
23Polyethylene glycol[1] Polyethylene glycol[1] D03370 --[7] 6, 78, 96, 97, 235, 276, 299
24Recifercept----[1] 276
25Recifercept (proposed INN)----[1] 276
26RECOMBINANT HUMAN GROWTH HORMONE[1] Somatotropin---[4] 78, 193, 265, 276
27Somatropin[1] Somatotropin---[19] 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299
28TA-46----[1] 276
29TBD----[5] 19, 86, 90, 276, 299
30TransCon CNP----[1] 276
31TransCon CNP 3.9 mg CNP-38/vial----[1] 276
32Vorsoritide----[1] 276
33Vosoritide[1] Vosoritide[1] D11190 [1] NPR2 💬[5] Metabolic pathways, Oxytocin signaling pathway, Purine metabolism, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 276